Blocking glutamate production from glutamine by GLS inhibition will down-regulate this important antioxidant pathway, resulting in higher ROS levels, which will be selectively toxic to cancer cells due to their increased local ROS levels (42). The gene discussed is GLS; the disease is cancer.